CYP4A10 Activators
CYP4A10 is a member of the cytochrome P450 superfamily of enzymes, which are key players in the metabolism of various substances in the body. These enzymes are involved in the oxidation of organic substances and play a crucial role in the metabolism of drugs, steroids, and other xenobiotics (foreign chemical substances).Specifically, CYP4A10 is part of the CYP4A subfamily. This subfamily is known for its role in the metabolism of fatty acids, particularly in the hydroxylation of medium and long-chain fatty acids. This process is important for maintaining homeostasis of lipid metabolism in the body. The CYP4A enzymes, including CYP4A10, are primarily found in the liver, but they are also present in other tissues.
CYP4A10, like other cytochrome P450 enzymes, is a heme-thiolate protein. This means it contains a heme (iron-containing) group, which is essential for its enzymatic activity. The activity of CYP4A10, as with other P450 enzymes, involves the insertion of an oxygen atom from molecular oxygen into its substrate (the fatty acid, in this case).The expression and regulation of CYP4A10 can be influenced by various physiological factors, including hormonal levels, dietary components, and the presence of certain drugs or xenobiotics. Alterations in the expression or activity of CYP4A10 can have implications for lipid metabolism and may be relevant in the context of certain metabolic disorders or diseases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Bezafibrate, another fibrate, also activates PPARs, leading to upregulation of CYP4A10, thereby enhancing fatty acid metabolism. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates PPARα, subsequently inducing CYP4A10 expression, which is involved in the metabolism of fatty acids, particularly in the liver. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
WY-14643 is a potent PPARα agonist that significantly increases CYP4A10 expression, thereby modulating fatty acid metabolism. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, primarily a PPARγ agonist, can indirectly influence CYP4A10 activity through PPAR-mediated pathways, affecting fatty acid and lipid metabolism. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, another PPARγ agonist, may indirectly enhance CYP4A10 expression through PPAR-related mechanisms, impacting fatty acid metabolism. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $49.00 $170.00 $267.00 $661.00 | 6 | |
GW7647, a PPARα agonist, enhances the expression of CYP4A10, thereby playing a role in fatty acid oxidation processes. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516, a PPARδ agonist, potentially affects CYP4A10 activity indirectly through PPAR-mediated signaling pathways, impacting fatty acid metabolism. | ||||||
L-165041 | 79558-09-1 | sc-203094 | 5 mg | $156.00 | ||
L-165041, a PPARδ agonist, may influence CYP4A10 expression indirectly, thus affecting the metabolism of fatty acids and lipids. | ||||||
Ciglitazone | 74772-77-3 | sc-200902 sc-200902A | 5 mg 25 mg | $104.00 $428.00 | 10 | |
Ciglitazone, predominantly a PPARγ agonist, could indirectly modulate CYP4A10 activity by influencing PPAR-mediated pathways, particularly in lipid metabolism. | ||||||